Epigenetic biomarkers in the blood of patients with urological malignancies

Expert Review of Molecular Diagnostics

Volumn 15, Issue 4, 2015, Pages 505-516

  Ellinger, Jörg ^a   Müller, Stefan C ^a   Dietrich, Dimo ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

biomarker; bladder cancer; body fluids; DNA methylation; liquid biopsy; lncRNA; miRNA; prostate cancer; renal cell carcinoma; testicular cancer

Indexed keywords

ABIRATERONE; ENZALUTAMIDE; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 141; MICRORNA 143; MICRORNA 205; UNTRANSLATED RNA; TUMOR MARKER;

BLADDER CANCER; CHROMOSOMAL INSTABILITY; DISEASE MARKER; DNA CONTAMINATION; DNA METHYLATION; EPIGENETICS; FEMALE; FOLLOW UP; GERM CELL TUMOR; GLEASON SCORE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PARTIAL NEPHRECTOMY; PERSONALIZED MEDICINE; PROSTATE CANCER; REVIEW; RNA ISOLATION; URINARY TRACT CANCER; VALIDATION STUDY; BLOOD; GENETIC EPIGENESIS; GENETICS; PROCEDURES; UROLOGIC NEOPLASMS;

BIOMARKERS, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; MICRORNAS; RNA, LONG NONCODING; UROLOGIC NEOPLASMS;

EID: 84925680102     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1019477     Document Type: Review

References (101)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015. [Epub ahead of print]
2. Dietrich D, Meller S, Uhl B, et al. Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci 2014; 51(4):173-99
3. Waddington CH. The epigenotype. 1942. Int J Epidemiol 2012;41:10-13
4. Berger SL, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev 2009;23:781-3
5. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014;54:716-27
6. Weisenberger DJ. Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest 2014;124:17-23
7. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002;48:1647-53
8. Licchesi JD, Herman JG. Methylation-specific PCR. Methods Mol Biol 2009;507:305-23
9. Thomassin H, Kress C, Grange T. MethylQuant: a sensitive method for quantifying methylation of specific cytosines within the genome. Nucleic Acids Res 2004;32:e168
10. Hernandez HG, Tse MY, Pang SC, et al. Optimizing methodologies for PCR-based DNA methylation analysis. Biotechniques 2013;55:181-97
11. de Kok JB, Hendriks JC, van Solinge WW, et al. Use of real-time quantitative PCR to compare DNA isolation methods. Clin Chem 1998;44:2201-4
12. Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 2006;1075: 299-307
13. Ellinger J, Muller SC, Stadler TC, et al. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 2011;29:124-9
14. Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941-5
15. Reibenwein J, Pils D, Horak P, et al. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 2007;67:427-32
16. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-43
17. Ellinger J, Bastian PJ, Haan KI, et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 2008;122:138-43
18. Sunami E, Shinozaki M, Higano CS, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 2009;55:559-67
19. Ellinger J, Haan K, Heukamp LC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008;68: 42-9
20. Altimari A, Grigioni AD, Benedettini E, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 2008;129:756-62
21. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131-5
22. Chuang CK, Chu DC, Tzou RD, et al. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect Prev 2007;31:59-63
23. Wu T, Giovannucci E, Welge J, et al. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 2011;105:65-73
24. Mahon KL, Qu W, Devaney J, et al. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer 2014;111:1802-9
25. Roupret M, Hupertan V, Catto JW, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 2008;122:952-6
26. Dominguez G, Carballido J, Silva J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002;8:980-5
27. Valenzuela MT, Galisteo R, Zuluaga A, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 2002;42:622-8
28. Jablonowski Z, Reszka E, Gromadzinska J, et al. Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch Med Sci 2011;7:512-16
29. Lin YL, Sun G, Liu XQ, et al. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J Int Med Res 2011;39:179-86
30. Lin YL, Li ZG, He ZK, et al. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. J Int Med Res 2012;40: 2117-23
31. Luo ZG, Li ZG, Gui SL, et al. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer. J Int Med Res 2014;42:35-41
32. Ellinger J, El Kassem N, Heukamp LC, et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol 2008;179: 346-52
33. Hauser S, Kogej M, Fechner G, et al. Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res 2013;33: 779-84
34. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64: 5511-17
35. Hauser S, Zahalka T, Fechner G, et al. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res 2013;33:4651-6
36. Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12:6989-97
37. de Martino M, Klatte T, Haitel A, et al. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 2012;118:82-90
38. Kawakami T, Okamoto K, Ogawa O, et al. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 2004;363:40-2
39. Ellinger J, Albers P, Perabo FG, et al. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol 2009;182:324-9
40. Farazi TA, Hoell JI, Morozov P, et al. MicroRNAs in Human Cancer. Adv Exp Med Biol 2013;774:1-20
41. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8
42. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66
43. Spizzo R, Nicoloso MS, Croce CM, et al. SnapShot: microRNAs in Cancer. Cell 2009;137:586-6.e1
44. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-41
45. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci 2012;37:460-5
46. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012;18:883-91
47. Chevillet JR, Kang Q, Ruf IK, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA 2014;111:14888-93
48. Gallo A, Tandon M, Alevizos I, et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7:e30679
49. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39:7223-33
50. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-33
51. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012;5: 492-7
52. Starkey Lewis PJ, Merz M, Couttet P, et al. Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther 2012;92:291-3
53. Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol 2012;7:1528-33
54. Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011;6:e25787
55. Wang K, Yuan Y, Cho JH, et al. Comparing the MicroRNA spectrum between serum and plasma. PLoS One 2012;7:e41561
56. Farina NH, Wood ME, Perrapato SD, et al. Standardizing analysis of circulating microRNA: clinical and biological relevance. J Cell Biochem 2014;115:805-11
57. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105: 10513-18
58. Kroh EM, Parkin RK, Mitchell PS, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301
59. Li Y, Kowdley KV. Method for microRNA isolation from clinical serum samples. Anal Biochem 2012;431:69-75
60. Sanders I, Holdenrieder S, Walgenbach-Brunagel G, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol 2012;19:1017-25
61. Watahiki A, Macfarlane RJ, Gleave ME, et al. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci 2013;14:7757-70
62. Gonzales JC, Fink LM, Goodman OB Jr, et al. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 2011;9:39-45
63. Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011;32:583-8
64. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16
65. Westermann AM, Schmidt D, Holdenrieder S, et al. Serum microRNAs as Biomarkers in Patients Undergoing Prostate Biopsy: results from a Prospective Multi-Center Study. Anticancer Res 2014;34:665-9
66. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71:550-60
67. Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011;77:1265 e9-16
68. Singh PK, Preus L, Hu Q, et al. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 2014;5:824-40
69. Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 2013;8:e69239
70. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011;71:326-31
71. Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer. Eur Urol 2015;67:33-41
72. Jiang X, Du L, Wang L, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 2015;136(4):854-62
73. Scheffer AR, Holdenrieder S, Kristiansen G, et al. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 2014;32:353-8
74. Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2013;31: 1701-8
75. Hauser S, Wulfken LM, Holdenrieder S, et al. Analysis of serum microRNAs (miR-26a-2∗, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol 2012;36: 391-4
76. Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012;10:55
77. Zhao A, Li G, Peoc'h M, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013;94:115-20
78. Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol 2014;44:53-8
79. Teixeira AL, Ferreira M, Silva J, et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 2014;35:4057-66
80. Belge G, Dieckmann KP, Spiekermann M, et al. Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors? Eur Urol 2012;61:1068-9
81. Dieckmann KP, Spiekermann M, Balks T, et al. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer 2012;107:1754-60
82. Syring I, Bartels J, Holdenrieder S, et al. Circulating serum microRNA (miR-367-3p, miR-371a-3p, miR-372-3p, miR-373-3p) as biomarkers for patients with testicular germ cell cancers. J Urol 2015;193(1):331-7
83. Gillis AJ, Rijlaarsdam MA, Eini R, et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol Oncol 2013;7:1083-92
84. Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 2012;31:4577-87
85. Martens-Uzunova ES, Bottcher R, Croce CM, et al. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol 2013;65:1140-51
86. Du Z, Fei T, Verhaak RG, et al. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol 2013;20:908-13
87. Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013;45: 1392-8
88. Prensner JR, Zhao S, Erho N, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol 2014;15:1469-80
89. Sowalsky AG, Xia Z, Wang L, et al. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 2015;13:98-106
90. Kohls K, Schmidt D, Holdenrieder S, et al. Detection of cell-free lncRNA in serum of cancer patients. Urologe A 2014. [Epub ahead of print]
91. Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 2013;49:2949-59
92. Xue D, Zhou CX, Shi YB, et al. MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level. Tumour Biol 2015. [Epub ahead of print]
93. Crea F, Watahiki A, Quagliata L, et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 2014;5:764-74
94. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers 2007;23:73-87
95. The Cancer Genome Atlas. Available from: http://cancergenome.nih.gov
96. Poste G. Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. Trends Mol Med 2012;18:717-22
97. Guidance for industry bioanalytical method validation. Available from: www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf
98. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60: 1205-19
99. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6:255-61
100. University Bremen: miRdetect. Available from: www.uni-bremen.de/mirdetect.html
101. Wang S, Zhao X, Khimji I, et al. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab Chip 2011;11:3411-18